Skip to main content
. 2022 Aug 19;11(16):2582. doi: 10.3390/cells11162582

Figure 2.

Figure 2

Mitochondrial effects of CB1 activation in eWAT. (A) WIN 5 µM effect (relative to vehicle, V) on complex I activity in eWAT from WT, CB1-KO, and DN22-CB1-KI mice. (B) Oxygen consumption rate (OCR) in eWAT homogenates from WT mice. MPG, malate pyruvate glutamate; ADP, adenosine di-phosphate; Cyt.C, cytochrome C; Ama, antimycin A. The gray area indicates complex-I-dependent respiration (OXPHOS) used for testing cannabinoid agonist effects. (C–F) Time course of the WIN effect on the oxygen consumption rate (OCR) in eWAT homogenates from WT (C), CB1-KO (D), Ati-CB1-KO (E), and DN22-CB1-KI (F) mice. The OXPHOS phase represents complex-I-dependent respiration (see B); LEAK, oligomycin-dependent ATP synthase inhibition; ETS, electron-transfer-system in an uncoupled state (by the addition of carbonyl cyanide m-chlorophenylhydrazone). The grey area indicates WIN (or vehicle) administration. (G) The WIN effect (relative to vehicle, V) on complex-I-dependent OXPHOS respiration in eWAT homogenates from WT, CB1-KO, Ati-CB1-KO, and DN22-CB1-KI mice calculated from panels (C–F), respectively. ** p < 0.01 from vehicle. # p < 0.05 from WT.